Marinomed Biotech AG

Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios

Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets

Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico

Change of total number of voting rights and capital according to article 135 section 1 BörseG

Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months

Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe

Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations

Change of total number of voting rights and capital according to article 135 section 1 BörseG

Marinomed Biotech AG announces preliminary revenue for 2023

Marinomed Biotech AG with important progress for Carragelose in 2024

Marinomed Biotech AG evaluates strategic options for Carragelose portfolio

Marinomed Biotech AG evaluates strategic options for Carragelose portfolio

Marinomed Biotech AG with new Carragelose distribution and manufacturing partners and EU patent

Marinomed Biotech AG: Stable revenues in the first three quarters of 2023 and further progress in business development

Marinomed Biotech AG resumes Nice & Green Convertible Notes Funding Program with reduced volume

Marinomed Biotech AG reports record revenues in the first half of the year and pushes business development activities

Marinomed enters first long-term Solv4U partnership with Shanghaibased SPH Sine Pharmaceutical Laboratories Co. Ltd.

Marinomed Biotech AG: M8 Pharmaceuticals obtains market authorization for Carragelose nasal spray in Mexico

Peer-reviewed publication by Marinomed Biotech AG and Friedrich-Alexander-University Erlangen-Nürnberg reconfirms broad virus-blocking effectiveness of iota-carrageenan

Marinomed Biotech AG: Annual General Meeting elects Dr. Eva Hofstädter-Thalmann as a new member of the Supervisory Board

Marinomed Biotech AG prepares launch of Carragelose eye drops in 2024

Marinomed Biotech AG reports best first quarter in company history

Marinomed Biotech AG with Carragelose record sales in 2022 and positive outlook for 2023

Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever

Marinomed Biotech AG reports positive clinical data for the Carragelose decongestant nasal spray

Marinomed Biotech AG announces preliminary revenue for 2022 with double-digit growth for Carragelose

Marinomed Biotech AG: Marinomed Biotech receives US Patent approval for the Marinosolv® technology and invests in a series of new patents